JAMA: studies find little evidence to support genetic testing to improve CV risk assessment Reply

Two separate studies appearing in JAMA cast doubt on the practical value of genetic testing to improve cardiovascular risk assessment.

In the first study, Nina Paynter and colleagues, led by Paul Ridker, calculated genetic risk scores based on 101 SNPs (single nucleotide polymorphisms) from 19,313 women enrolled in the Women’s Genome Health Study. They found that after adjusting only for age, patients in the lowest tertile of genetic risk had a CV risk of 3% over 10 years, compared to a risk of 3.7% for those in the highest tertile. However, once the investigators adjusted for traditional risk factors, the genetic risk score no longer provided additional information of value. By contrast, “self-reported family history remained significantly associated with cardiovascular disease in multivariable models.”
Click to continue reading…

Boston Scientific CEO: were the reports of ICD flaws tied to attempts to drive down the stock price? Reply

(Updated with a statement from Douglas Zipes, the editor of Heart Rhythm)– The CEO of Boston Scientific, Ray Elliott, has implied that recent publicity about an article in Heart Rhythm involving a flawed Boston Scientific ICD somehow may be tied to attempts to drive down the stock price of the company. Elliott made his remarks during the Boston Scientific quarterly earnings call on Thursday. (See our previous stories about the ICD problem here and here. Here are links to the Heart Rhythm article, a letter to the editor from Boston Scientific scientists, and a response to the letter from the article’s authors.)

In his remarks, a clearly agitated Elliott said the journal “was completely out of line to publish this article prematurely” and then remarked:
Click to continue reading…

Roche announces more positive results for taspoglutide, but… Reply

Roche announced more positive phase III results from its promising diabetes drug taspoglutide, but the announcement may not have amounted to the tsunami of new results that the press release seemed to promise.

Today’s press release (reprinted below) said that “results from the first five Phase III clinical trials show that taspoglutide has met the primary end-points of reduction in blood glucose (blood sugar) in these studies.” However,  4 of the 5 studies were the subjects of similar announcements by Roche in December. (You can read the CardioBrief stories here and here.)
Click to continue reading…

Rosuvastatin (Crestor) gains expanded primary prevention indication 1

The FDA today announced an expanded indication for rosuvastatin (Crestor) for the primary prevention of cardiovascular disease. The decision follows a positive vote last December by an FDA advisory panel.

Notably, the new label does not endorse the use of rosuvastatin for everyone with elevated CRP levels and does not contain an indication for the reduction of total mortality or cardiovascular death. Sanjay Kaul, who served on the FDA advisory panel and has been skeptical of a broad interpretation of JUPITER, provided the following comment: “The FDA recommendation for the use of Crestor is faithful to the evidence because in the JUPITER study individuals with less than two risk factors failed to derive significant treatment benefit. Furthermore, the label appropriately does not include a mortality indication.”

Click to continue reading…

Study finds significant lesions in one-fifth of patients with zero calcium scores 3

A calcium score of zero does not completely rule out significant coronary disease, according to the surprising results of a substudy of the CORE64 multicenter trial, in which patients referred for angiography were also asked to undergo a calcium scan. Ilan Gottlieb and colleagues report in the Journal of the American College of Cardiology on 291 patients enrolled in the study, of whom 72 had a calcium score of zero. 14 of these patients (19%) had at least one lesion with > 50% stenosis. In the study as a whole there were 64 totally occluded vessels, of which 13 (20%) had no calcium. 9 patients with no calcium underwent revascularization.
Click to continue reading, including comments from Rita Redberg, PK Shah, and Matthew Budoff…

New concerns raised about Boston Scientific ICDs 2

Updated with remarks from William Maisel and a statement from Boston Scientific– A case of a weakened bond between the header and case of a subcutaneously implanted Cognis CRT-D is raising new concerns about the Boston Scientific Cognis and Teligen ICDs. Last December Boston Scientific issued a product advisory based on two cases of a weakened header bond in ICDs that had been implanted subpectorally. Subpectoral implants account for approximately 5% of procedures, according to the company. Now, with the report of a weakened header bond in a Cognis ICD that had been implanted subcutaneously, concerns are being raised about a much larger number of devices that have already been implanted.
Click to continue reading…

The two sides of aspirin: too much and not enough 1

On the one hand, a lot of people who should be taking aspirin aren’t doing so. On the other hand, a lot of people who are taking aspirin shouldn’t be doing so. Those are the dual conclusions of a new report and accompanying editorial from the REACH Registry appearing in the American Journal of Cardiology.

Chris Cannon and fellow REACH registry investigators analyzed data from more than 25,000 US patients with vascular disease or multiple risk factors and found that only 70% were taking aspirin. Approximately half of these were taking other antithrombotic agents, but the other half– 15% of the study population– were not receiving any antithrombotic therapy.
Click to continue reading…

Live AF ablation broadcast on Today Show: what’s wrong with this picture? 17

Mauricio Arruda performed a live AF ablation at University Hospitals in Cleveland on the Today Show yesterday morning.

The 6-minute segment was relentlessly upbeat. The TV producers pulled every trick in the book to overcome the inherent difficulty of portraying a hard-to-explain disease like AF and an even harder-to-explain procedure like catheter ablation. Instead of making any effort to truly educate their viewers, the producers took the easy route. Arruda, staring at a bank of large display monitors, might as well have been playing a video game, for all anyone watching might have known. And the reporter, NBC Medical correspondent Dr Nancy Snyderman, substituted schmaltz for substance and presented the “heartwarming” story of the patient, a great-grandmother, accompanied by stirring music and sentimental images.
Click to continue reading…

Alderman in JAMA: universal sodium reductions are a “rash route” 2

In the absence of “definitive evidence,” universal dietary sodium reductions are a “rash route,”  writes Michael Alderman in a JAMA commentary. Although measures to cut salt have been gaining widespread support– see the recent study and editorial in the NEJM, as well as a detailed discussion of US efforts to cut salt in heartwireAlderman says these measures have not been validated, and he calls for “large-scale, population-based randomized clinical trials.”
Click to continue reading…

Guest Post: Chantix and Cardiovascular Risk: Another Weak Safety Study 3

Editor’s Note: The following is a guest post by Joseph Ross, an assistant professor at the Mt Sinai School of Medicine. This post originally appeared on CardioExchange, an online cardiology community in the early stages of development by the New England Journal of Medicine. The editor-in-chief of CardioExchange is Harlan Krumholz, who frequently collaborates with Ross. CardioBrief’s Larry Husten is the news editor of CardioExchange.

Chantix and Cardiovascular Risk: Another Weak Safety Study

by Joseph S. Ross, MD, MHS

In 2008, Dr. John Spangler of the Wake Forest University School of Medicine wrote a letter to the editor of Current Medical Research and Opinion expressing concern about a Pfizer-funded, randomized, placebo-controlled trial of the smoking-cessation drug varenicline (Chantix). By 1 year, the varenicline group had experienced a higher rate of serious adverse events than the placebo group; many were cardiovascular (CV) events. The difference was not statistically significant, but Spangler considered it clinically significant and deserving of further study.
Click to continue reading…

Study identifies shortcut to diagnosing long QT syndrome Reply

Observing the QT interval when a patient stands up quickly can provide a simple and quick method to identify patients who may have Long QT syndrome (LQTS), according to Sami Viskin and colleagues in an expedited study in JACC.

The researchers studied 68 patients with LQTS and 82 controls. Each subject had a baseline ECG while lying down and was then asked to stand up quickly. Both groups had a similar heart rate acceleration in response to standing, but significant differences were found in the response of the QT interval.
Click to continue reading…

Lancet: researchers find Goldilocks effect in glucose control for diabetes Reply

It turns out that blood glucose may be a lot like porridge, and that physicians, like Goldilocks, need to get it just right. In a new study appearing online first in the Lancet, researchers from Cardiff, UK and Eli Lilly examined data from 48,000 patients in the UK General Practice Research Database. All cause mortality was lowest in those who achieved an HbA1c level of 7.5%. Mortality increased as HbA1c levels increased or decreased from this level, which the investigators described as a U-shaped association. The analysis was adjusted for age, sex, smoking status, cholesterol, cardiovascular risk, and general morbidity.

Click to continue reading…

Cath lab coming attractions: 3D images of the coronary arteries 1

It may not be as sexy as Avatar in 3D at the local Imax, but recent advances in technology may one day allow cardiologists to see 3D images of the coronary arteries in the catheterization lab, according to a new feasibility study published in Circulation: Cardiovascular Interventions.

The new system uses existing X-ray systems in the cath lab and may decrease patient exposure to radiation and contrast dye, say the study’s authors, led by John Carroll at the University of Colorado, and including researchers from Philips. The study compared standard 2-D images to automatically generated, computer-reconstructed 3-D images in 23 patients. The images were obtained using rotational angiography and ECG gated iterative reconstruction.
Click to continue reading…

JAMA: RF ablation superior to drugs in multicenter AF trial Reply

Catheter ablation of AF was superior to antiarrhythmic drugs in the ThermoCool AF Trial, according to a new report in JAMA.

Led by David Wilber, the trial investigators randomized 167 patients at 19 hospitals to the multicenter, randomized trial. The primary endpoint was the time to protocol-defined treatment failure within the 9 month evaluation period. At 9 months, 66% of the catheter ablation group were failure free, compared with only 16% of patients receiving drug therapy. At 30 days, major treatment-related adverse events had occurred in 8.8% of the drug therapy group versus 4.9% of the ablation group. In addition, quality of life was significantly better improved in the ablation group.
Click to continue reading…

FDA approves first percutaneous heart valve, Medtronic’s Melody Pulmonary Valve 2

The FDA today approved the Medtronic Melody Transcatheter Pulmonary Valve and Ensemble Delivery System. It is the first percutaneous valve to receive FDA approval. The Melody valve is intended to help patients with poorly functioning pulmonary valve conduits delay the need for open-heart surgery.

The device was approved for use under the FDA’s Humanitarian Device Exemption (HDE) program. Use of the valve will therefore only be used at hospitals that have an Institutional Review Board. In October 2006, the valve received the CE mark in Europe, becoming the the first transcatheter valve to receive regulatory approval anywhere in the world.
Click to continue reading, including press releases from the FDA and Medtronic…

Sandoz starts to prepare for generic enoxaparin in the US 1

A generic form of enoxaparin (Lovenox) may be available in the US sooner than expected, according to Sanford Bernstein analyst Timothy Anderson. In partnership with the biotech company Momenta, Sandoz, the generic arm of Novartis, has been setting prices and soliciting pre-orders for generic enoxaparin, writes Anderson in a research report. “This covert action suggests Novartis believes approval of its generic might finally be nearing.”
Click to continue reading…

Abbott suspends marketing of sibutramine in Europe following EMEA warning (updated) Reply

Updated–Following a recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) that sibutramine be withdrawn from European markets, Abbott announced today that it had suspended marketing of the drug in Europe.  The events in Europe  closely follow an announcement earlier in the day from the US FDA that sibutramine will now be contraindicated in people with cardiovascular disease. Abbott said sibutramine would remain available outside the EU.

Click to continue reading…

Generic clopidogrel besilate makes inroads into European Plavix market Reply

Generic versions of clopidogrel with the alternate besilate salt form have started to capture substantial portions of the Plavix/Iscover (clopidogrel bisulfate) market, according to a research report from Sanford Bernstein analyst Timothy Anderson. Many European countries– but not the US–  consider alternative salt forms of drugs to be acceptable generic equivalents.
Click to continue reading…